Business Wire

30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased

16.7.2025 09:15:00 CEST | Business Wire | Press release

Share

Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life.

Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health.

The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein.

This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily intake of spermidine. Spermidine is associated with benefits to longevity, cardiovascular health and brain health.

The paper states that “during (Almased’s) proteolytic enzyme procedure, bioactive and biogenic peptides, which were not detectable before in the raw materials, naturally occur. It can be assumed that the production process is significant in producing bioactive compounds responsible for unexpected positive effects on the metabolism, even in people who are not overweight”.

Other key findings in the 2022 review in Heliyon have shown:

  • 167% increase in GLP-1 production and a 358% increase in PYY production (a satiety-induced hormone produced in the intestine) compared to consuming a standard American diet containing the same amount of calories by the same individuals (Oliveira et al. 2022)
  • Almased group lost 145% more weight than the control group (-13lbs vs. -5.3lbs) in 12 weeks. Fat loss was 181% more in the Almased group (-9.9 lbs) than in the control group (-3.52 lbs) over the same period of time despite comparable weights before the study (Röhling et al. 2020)
  • Almased plus resistance training increased muscle strength by 33% versus resistance training alone (Deibert et al 2010)
  • Waist circumference reduction 239% greater in the Almased group compared to a fat-reduced diet (2.4in vs. 0.7in) after 6 weeks. Fat mass loss was 82% greater in the Almased group compared to a fat-reduced diet (11.2lbs vs. 6.1lbs) after 6 weeks (König et al 2008)
  • A study on post-menopausal women saw a 62% reduction in the prevalence of metabolic syndrome and significant fat loss without losing lean mass (Deibert et al. 2007)
  • Almased reduced liver fat content by an average of 56% and supports a healthy inflammatory response (Deibert et al 2019)
  • Almased preserved 100% muscle mass while losing weight (Deibert et al 2004)

Researchers found that Almased improves the fat burning process so you burn fat and calories more effectively (Oliveira et al 2021). In overweight and obese individuals, Almased meal replacement regimens resulted in greater reductions in body weight, body mass index (BMI), and fat mass compared to traditional low-calorie diets, while also improving glycemic control and lipid profiles.

Beyond weight management, the review highlights Almased’s role in supporting healthy blood sugar levels in both prediabetic and type 2 diabetic individuals. This indicates Almased is safe for people with diabetes.

The review also notes Almased’s unique anti-aging and wellness benefits. Regular use has been linked to healthy cell function, reduced stress markers, and better overall energy and mood. Almased’s protein-rich formula, containing essential amino acids and bioactive peptides, supports muscle preservation, cellular health, and supports a healthy inflammatory response, contributing to improved quality of life and longevity.

“The results presented underscore the efficacy of the soy-yogurt-honey formula (Almased) in weight management and the improvement of obesity-associated cardiovascular disease and metabolic risk factors.” said the study’s authors.

About Almased

Founded over 30 years ago in Germany by holistic therapist Hubertus Trouillé, and his son Andre Trouillé, Almased is a family-owned and operated company dedicated to promoting health and wellness worldwide. Recognized as Europe’s #1 science backed weight-loss meal replacement shake brand, Almased combines natural ingredients with a patented fermentation process to deliver high-quality, effective nutrition. With over 30 peer reviewed studies across 3 decades, Almased is a global leader in metabolic health. With a commitment to sourcing the highest quality ingredients in the world, Almased continues its mission to help people achieve healthier, happier lives with clean, sustainable products.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250716374177/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release

Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin

Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and

Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 12:17:00 CEST | Press release

Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm

Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 11:11:00 CEST | Press release

- Medical oncologist and accomplished clinical leader brings deep development and industry experience to Mosaic’s Executive Leadership team - Vince will lead research and development for Mosaic’s drug combination programs, including the build-out of the Company’s early pipeline Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechno

The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 09:00:00 CEST | Press release

New One-Day Intensive Experience Offered 9 June Ahead of Conference 10-11 June at Tobacco Dock Featuring 10 Stages and 14 Tracks The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye